i-Lumen Scientific has enrolled the first U.S. patient in i-SIGHT2, a pivotal trial testing bioelectric microcurrent stimulation delivered through the eyelid to restore retinal function in intermediate to advanced dry age-related macular degeneration. The therapy aims to repolarize retinal pigment epithelium cells and improve photoreceptor function, addressing a condition with limited treatment options.
Key Points
- Bioelectric microcurrent stimulation targets retinal pigment epithelium repolarization
- Prior feasibility data showed improvements in visual function and structural biomarkers
- Office-based delivery through eyelid offers non-invasive treatment approach
Longevity Analysis
Age-related macular degeneration represents a significant driver of vision loss and functional decline in older populations, directly impacting quality of life and independence. A bioelectric approach to restore retinal cell function addresses the underlying cellular dysfunction rather than managing symptoms, potentially reversing early-stage vision loss. If efficacy is confirmed, this intervention could meaningfully extend the period of visual independence and reduce the trajectory of age-related sensory decline.
Original published by Longevity.Technology.